Beyond Antibiotics for Acne: What Retinoids, Hormonal Therapy, and New Prescriptions Actually Do

Research-informed explainer — last updated April 12, 2026

Topical retinoids — not antibiotics — are now the cornerstone of evidence-based acne treatment for most patients, and the global movement away from long-term antibiotic monotherapy is reshaping how dermatologists approach every severity of acne. For moderate-to-severe disease, hormonal therapy, isotretinoin, and newer targeted agents offer durable outcomes that antibiotics alone cannot match.

This article draws on research from five dermatology specialists. Dr. Carol Cheng, Director of the Acne/Rosacea Clinic at UCLA, co-authored the 2024 AAD guidelines for acne management (340 citations) — the current standard reference for when antibiotics are and are not appropriate. Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medicine, contributed the international practical acne management consensus (410 citations) and skin-of-color acne epidemiology (221 citations), highlighting how the same diagnosis calls for different treatment priorities depending on patient background. Dr. Jonathan Weiss of Emory University contributed multicenter trials comparing adapalene to tretinoin (185 citations), the adapalene-benzoyl peroxide fixed combination (182 citations), and authored a review of why topical retinoids remain the cornerstone of acne therapy (152 citations). Dr. Bernard Cohen, Professor of Dermatology and Pediatrics at Johns Hopkins, reviewed the case for moving away from antibiotic-first strategies in a 2020 Pediatrics review (173 citations). Dr. Jeffrey Orringer of Michigan Medicine contributed the first JAMA-published randomized controlled trial of pulsed dye laser for acne (173 citations) and research on dermal microenvironment remodeling (229 citations).

Why antibiotics alone are not the answer

Antibiotics kill or inhibit Cutibacterium acnes (formerly P. acnes), the bacteria that contribute to acne inflammation. For decades, oral tetracyclines and topical antibiotics were the backbone of acne treatment. The problem: prolonged antibiotic use drives resistance — both in C. acnes and in other bacteria — and does nothing to address the comedone formation (clogged pores) that is the root cause of all acne lesion types.

Cohen's 2020 Pediatrics review (173 citations) describes the global movement toward restricting antibiotic use in acne to short courses — typically 3 months maximum — combined with non-antibiotic agents that prevent comedone formation and maintain remission without continued antibiotic exposure. The 2024 AAD guidelines co-authored by Cheng (340 citations) formalize this approach, recommending topical retinoids as first-line for almost all acne patients.

Topical retinoids: the evidence-based foundation

Topical retinoids (tretinoin, adapalene, tazarotene, trifarotene) work by normalizing keratinocyte turnover — preventing the abnormal shedding of skin cells inside follicles that creates the comedones underlying all acne. They also have direct anti-inflammatory effects.

Weiss co-authored the 1996 multicenter JAAD trial (185 citations) comparing adapalene 0.1% gel to tretinoin 0.025% gel: both reduced total lesion counts significantly, but adapalene produced less skin irritation — a clinically important practical difference because irritation drives non-adherence. The 2017 Dermatology and Therapy review Weiss co-authored (152 citations) synthesized the evidence that retinoids are the only acne agents that prevent new comedone formation — making them irreplaceable even when combined with antibiotics.

Weiss also participated in the multicenter JAAD trial (182 citations) establishing the fixed-dose adapalene 0.1%/benzoyl peroxide 2.5% combination (now Epiduo): the combination achieved greater lesion reduction than either ingredient alone, and the BPO component helps prevent antibiotic resistance from developing in patients who need concurrent antibiotic therapy.

Starting a topical retinoid: Expect an initial "purge" period of 4–6 weeks during which acne may temporarily worsen as the retinoid unplugs existing microcomedones. Apply a pea-sized amount to dry skin, start 2–3 nights per week, and increase frequency as tolerated. Retinoids increase photosensitivity — sunscreen is essential.

Hormonal therapy for women

Androgens — testosterone and its derivatives — stimulate sebaceous glands to overproduce oil, a fundamental driver of acne in hormonally-sensitive patients. For women with acne that flares premenstrually, or who have other signs of androgen excess (irregular periods, hirsutism), hormonal therapy addresses the root cause.

Combined oral contraceptives (COCs): Three formulations are FDA-approved for acne — norgestimate/ethinyl estradiol (Ortho Tri-Cyclen), norethindrone acetate/ethinyl estradiol (Estrostep Fe), and drospirenone/ethinyl estradiol (Yaz). They work by suppressing ovarian androgen production and raising sex hormone-binding globulin, which reduces free testosterone. Typically require 3–4 months to see full benefit.

Spironolactone: An aldosterone antagonist that blocks androgen receptors in sebaceous glands. Off-label for acne but widely used; typical doses of 50–150 mg/day. Requires avoidance of pregnancy (teratogenic). The 2024 AAD guidelines (Cheng) and the international consensus (Alexis) both support spironolactone as a highly effective hormonal option, particularly for adult women with late-onset or treatment-resistant acne.

Clascoterone cream 1% (Winlevi): The first topical antiandrogen approved for acne, available for patients aged 12 and older. Applied twice daily; inhibits androgen receptors at the sebaceous gland level without systemic hormonal effects — an option for both male and female patients where systemic hormonal therapy is not appropriate or desired.

Isotretinoin: who needs it and what to expect

Isotretinoin (Accutane and generics) remains the most effective acne treatment available — the only drug that addresses all four pathogenic factors simultaneously (sebum production, comedone formation, inflammation, and C. acnes proliferation). It produces lasting remission in 85% of patients after a single course.

Cohen's 2020 review (173 citations) notes that isotretinoin has progressively expanded from its original indication for nodulocystic acne to become the drug of choice among dermatologists for moderate-to-severe acne of any type that has not responded to adequate topical and antibiotic therapy.

Who should consider isotretinoin:

• Nodular or cystic acne (large, painful, deep bumps)
• Acne causing significant scarring
• Moderate acne that has not responded to 3–6 months of appropriate topical and oral therapy
• Acne with significant psychological burden regardless of clinical severity

What isotretinoin requires:

• iPLEDGE program enrollment (mandatory FDA safety program) — monthly pregnancy tests for patients who can become pregnant
• Monthly liver function and lipid monitoring
• Strict sun protection
• Mental health monitoring (rare but reported association with mood changes; causality is debated)

Cheng's 2010 epidemiological study (165 citations) in the Journal of the European Academy of Dermatology found that acne prevalence and sequelae including scarring were more common in darker-skinned women — underscoring why early aggressive treatment with isotretinoin when appropriate is particularly important in these populations to prevent post-inflammatory hyperpigmentation and scarring that can be more persistent and disfiguring.

Newer prescription options

Sarecycline: A narrow-spectrum oral tetracycline antibiotic with anti-inflammatory properties and reduced activity against gut flora compared to doxycycline — potentially minimizing antibiotic resistance risk while maintaining efficacy for moderate-to-severe inflammatory acne.

Tazarotene 0.045% lotion (Arazlo): A newer retinoid formulation with improved tolerability versus older tazarotene concentrations, approved for acne in patients 9 and older.

Trifarotene 0.005% cream (Aklief): The first retinoid selective for the RAR-gamma receptor, which is highly expressed in skin. Particularly studied for truncal (chest and back) acne in addition to facial acne.

Light-based and procedural options

Orringer's 2004 JAMA trial (173 citations) established the first RCT evidence for pulsed dye laser in acne — a 12-week study showing a statistically significant reduction in inflammatory lesions. Light-based approaches (pulsed dye laser, photodynamic therapy, blue light) are adjunctive rather than primary therapies but can be meaningful additions for patients with residual inflammatory papules despite optimized topical and systemic treatment.

Skin-of-color considerations

Alexis's 2007 PubMed survey (221 citations) documented that acne was the leading dermatologic complaint in Black patients at a skin-of-color specialty center. Beyond the higher prevalence, treatment choices require sensitivity to post-inflammatory hyperpigmentation (PIH) risk — darker skin tones develop PIH more readily from both untreated inflammatory acne and from treatment irritation. This argues for:

• Gentle formulations and slow retinoid uptitration to minimize irritation-driven PIH
• Early incorporation of azelaic acid or niacinamide for PIH alongside acne treatment
• Careful attention to whether scarring is keloid-prone, which affects procedural decision-making

Questions to ask your doctor

• Should I be on a retinoid, and if so, which one is appropriate for my skin type and sensitivity?
• Have I been on antibiotics for acne long enough that resistance is now reducing their benefit?
• If I am a woman with adult-onset acne, is there a hormonal driver — and would spironolactone or an oral contraceptive make sense?
• At what point in my treatment history is isotretinoin the right next step?
• If I have dark skin and prone to hyperpigmentation, are there specific treatments I should start or avoid?
• Are there in-office procedures (chemical peels, laser) that would help with my existing scarring while treating active breakouts?

The bottom line

The evidence is clear: topical retinoids should be part of almost every acne treatment plan as the foundation that addresses comedone formation, while antibiotics should be used only as short courses when inflammatory disease is active and always in combination with a retinoid. For women with hormonal acne, spironolactone and combined oral contraceptives address the androgen driver that topicals alone cannot reach. For patients with persistent moderate-to-severe acne or significant scarring, isotretinoin remains the most effective long-term solution available — and a dermatologist experienced in acne management can guide you through the iPLEDGE program safely.